ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of cancers and for the purpose of testing ALRN-6924 as a therapeutic agent that can protect cancer patients from chemotherapeutic toxicities (“Myelopreservation Trial”).  Preliminary clinical results have demonstrated a favorable safety profile and evidence of durable antitumor activity.

Our ongoing clinical trials of ALRN-6924 include:

  • Phase 2a trial in combination with Palbociclib for MDM2 amplified or MDM2/CDK4 co-amplified solid tumors

  • Phase 1b/2 trial of ALRN-6924 as a myelopreservation drug in SCLC patients treated with topotecan (enrollment start planned for September 2019)

Past clinical trials of ALRN-6924:

  • Phase 1 trial for the treatment of acute myeloid leukemia (AML), and advanced myelodysplastic syndrome (MDS), as a monotherapy

  • Phase 1b trial for the treatment of AML/MDS in combination with cytosine arabinoside (Ara-C)

  • Phase 2a trial for the treatment of peripheral T-cell lymphoma (PTCL)

For more information, access our ongoing trial updates at https://clinicaltrials.gov/